Current Treatments for Low Sexual Desire in Young Women Reviewed

Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition characterized by a persistent or recurrent deficiency of sexual fantasies and desire for sexual activity. It significantly impacts the quality of life for many women, particularly younger individuals. Despite its prevalence, comprehensive and up-to-date summaries of effective treatment strategies specifically for young women with HSDD are often fragmented, necessitating a consolidated overview.

The review identified several promising therapeutic avenues for HSDD in young women. Flibanserin, an 5-HT1A agonist and 5-HT2A antagonist (modulating serotonin in the brain), demonstrated modest but statistically significant improvements in satisfying sexual events (SSEs), with studies reporting an average increase of 0.5-1.0 SSEs per month compared to placebo. Bremelanotide, a melanocortin receptor agonist, was found to increase sexual desire scores by 1.2 points on a 6-point scale and SSEs by 0.6 per month in premenopausal women. Both pharmacological and non-pharmacological interventions, including cognitive behavioral therapy (CBT) and mindfulness-based approaches, showed efficacy, with CBT often leading to a 30-50% reduction in distress associated with low desire. Testosterone therapy, while not FDA-approved for HSDD in women, showed potential benefits in some studies, with increases in sexual desire scores by ~0.8 points and SSEs by ~0.5 per month, though concerns regarding long-term safety and appropriate dosing (300 mcg/day transdermal) remain. Non-pharmacological strategies consistently improved sexual function and satisfaction, often without the side effects associated with drug treatments.